Rapamycin for Longevity: What the PEARL Trial Actually Found After 48 Weeks in Humans

TL;DR: The PEARL trial is the first rigorous, year-long, placebo-controlled human study of rapamycin for healthy aging. The drug did not reduce belly fat (the primary goal), but women taking 10mg weekly gained 5% lean tissue mass and reported significant pain reduction after 48 weeks. The safety profile was favorable. Epigenetic clock data was not measured. This is promising early evidence, not proof of life extension.

[toc]

Why This Study Matters

For decades, rapamycin occupied an unusual position in aging science. Every model organism ever tested showed extended lifespan when given the drug. Yeast, worms, flies, and mice all lived longer. In 2009, the National Institute on Aging’s Interventions Testing Program fed rapamycin to mice starting at 600 days of age, roughly equivalent to 60 human years, and saw median lifespan extend by 9% in males and 14% in females. The drug worked even when started in middle-aged animals, a feat almost no other longevity compound can claim.

Yet no large, well-controlled human trial had asked the obvious next question: does any of this translate to people?

The PEARL trial was designed to answer that. It enrolled 114 healthy adults between 50 and 85, randomized them to placebo or low-dose weekly rapamycin, and tracked them for 48 weeks. Published in peer-reviewed form in 2025 (PMID 40188830), it is the most rigorous human data on rapamycin as a longevity intervention to date.

Before the PEARL results, the field was operating on animal data and small, short observational studies. Tens of thousands of people in the United States were already taking rapamycin off-label weekly with physician guidance, based entirely on theoretical extrapolation from mice. PEARL is the first attempt to find out whether that extrapolation holds.

The Study: Who, What, How

One caveat about the compounded form is important upfront. Laboratory testing found that 10mg of the compounded version used in PEARL delivered approximately 3mg of bioavailable rapamycin, and the 5mg dose delivered roughly 1.5mg. Participants in the “high dose” arm were effectively receiving a mid-range dose by pharmaceutical standards. The researchers noted this explicitly.

The drug itself has a striking origin. Rapamycin was isolated in 1972 from a soil bacterium called Streptomyces hygroscopicus, discovered on Easter Island. Its original function was antifungal defense. In humans, it became a cornerstone immunosuppressant for organ transplantation before the longevity field took notice in 2009.

What the Numbers Show

The primary endpoint did not move. Visceral adiposity showed no statistically significant change across any arm at 48 weeks.

The secondary results are more interesting.

Women in the 10mg group gained approximately 2.5% lean tissue mass by week 24 and approximately 5% by week 48 compared to their own baseline. These gains were statistically significant versus both the placebo group and the 5mg group. Men showed no significant lean mass change.

That 5% figure matters because of what rapamycin’s mechanism is supposed to do. mTOR functions as the cell’s master growth regulator. When nutrients are abundant, mTOR signals cells to grow and synthesize proteins. In aging muscle, mTOR becomes chronically hyperactivated in a way that paradoxically impairs protein synthesis and accelerates the loss of muscle tissue. Periodically blocking that hyperactivation with weekly rapamycin doses restores the muscle’s ability to respond to anabolic signals. The lean mass data in women appears consistent with that model.

Women in the 10mg group also reported statistically significant improvements in self-reported pain at both 24 and 48 weeks. Chronic low-grade inflammation, partly driven by the senescence-associated secretory phenotype (SASP) that mTOR helps sustain, is a known contributor to pain in aging. Participants in the 5mg group reported meaningful improvements in emotional well-being and general health perception.

On safety, adverse and serious adverse events were similar across all groups. No significant immunosuppression signals emerged at these low, weekly doses. Standard transplant-dose rapamycin carries well-documented infection risk. The intermittent weekly schedule is specifically designed to avoid sustained mTOR suppression while still delivering periodic cellular maintenance benefits. PEARL’s 48-week safety data supports that approach.

What the study did not measure: epigenetic clocks. GrimAge, DunedinPACE, and PhenoAge were not primary endpoints. A drug can improve lean mass and subjective pain without changing the underlying biological aging rate. Whether rapamycin moves epigenetic clocks in humans remains genuinely unknown from this trial.

What This Means for You (And What It Doesn’t)

Rapamycin is a prescription drug, not a supplement, and the PEARL results do not change that. The safety data covers 48 weeks at low intermittent doses in a selected healthy population. Long-term effects over years and interactions with individual health conditions are not characterized by this trial.

For women over 50 thinking about lean tissue preservation, the PEARL signal is worth tracking. Sarcopenia is the most underdiscussed threat to healthy aging in women after menopause. A 5% gain in lean mass over 48 weeks in a placebo-controlled trial is not noise.

For the broader longevity-interested population, the practical takeaway is about mechanism, not pharmacology. The pathways that rapamycin targets, mTOR inhibition, autophagy activation, and reduced SASP, are the same pathways activated by resistance training, caloric restriction, and time-restricted eating. You can meaningfully engage mTOR suppression without a prescription. These approaches are not as potent as pharmacological inhibition, but they carry no drug risks and decades of human safety data.

Muscle preservation is the most actionable priority in the 50 to 85 age range regardless of any rapamycin decision. Aim for 1.6 to 2.2g of protein per kilogram of body weight daily, combined with resistance training at least twice per week.

Optimum Nutrition Gold Standard 100% Whey is the best-studied protein supplement for muscle preservation in older adults. A 2023 Cochrane meta-analysis confirmed that whey protein combined with resistance training produces statistically significant lean mass gains in the 50 to 85 age group.

For a thorough, physician-written breakdown of rapamycin, mTOR, and the full longevity pharmacology landscape, Peter Attia’s Outlive: The Science and Art of Longevity covers the clinical reasoning behind off-label rapamycin use in detail, including dose rationale and what to monitor.

How This Fits With the Broader Evidence

The NIA’s Interventions Testing Program rapamycin-plus-acarbose combination study (Aging Cell 2022, PMC9741502) produced a 28% median lifespan increase in female mice and 34% in males. Acarbose, a generic diabetes drug that slows carbohydrate absorption and activates AMPK, complements rapamycin by hitting the mTOR network from a second direction simultaneously. The combination produced the largest longevity effect in ITP history.

A 2025 study combining rapamycin with the MEK inhibitor trametinib produced a 30% average lifespan extension in mice, alongside preserved cognitive function and reduced tumor burden. In animal models, mTOR inhibition appears to reduce, not increase, tumor risk at these doses.

The TAME trial, targeting aging with metformin in 3,000 adults across 14 US research sites, is running in parallel. Metformin shares pathway overlap with rapamycin through AMPK activation and indirect mTOR modulation. TAME results will help answer whether AMPK-targeting drugs produce measurable epigenetic clock deceleration in humans, the data point missing from PEARL.

The picture that emerges is of a set of interventions, rapamycin, acarbose, metformin, and vigorous exercise, all converging on the same core biology: reducing chronic mTOR hyperactivation to allow cellular maintenance pathways to run. PEARL moved this from theoretical to empirically supported in humans, at least for 48 weeks.

FAQ

Is rapamycin legal to take for longevity?

Yes. Rapamycin is FDA-approved as an immunosuppressant for transplant patients. Physicians can legally prescribe it off-label for any purpose they judge clinically appropriate. It is a prescription drug. Obtaining it without a prescription involves importing from international pharmacies, which sits in a legal gray area in most jurisdictions.

What dose do longevity physicians typically use?

The most common protocol is 5 to 10mg of compounded rapamycin once weekly. Based on PEARL’s bioavailability data, compounded 10mg delivers approximately 3mg of pharmaceutical-grade equivalent. Doses are individualized based on monitoring, not fixed protocols.

Does rapamycin extend human lifespan?

No human trial has demonstrated lifespan extension. Rapamycin robustly extends lifespan in multiple animal species, including mice started at mid-life. PEARL measured healthspan endpoints over 48 weeks, not lifespan. Whether the drug extends human lifespan remains genuinely unknown.

Why didn’t PEARL measure epigenetic clocks?

The trial was designed before epigenetic clock measurement became standard in longevity research. A separate 12-week intermittent rapamycin study in healthy adults showed reductions in DNA methylation aging markers, but it was smaller and shorter than PEARL. Future trials will likely include clock measurement as a primary endpoint.

Who should not take rapamycin?

People with active infections, compromised immune function, poor wound healing, pregnancy, or uncontrolled hyperlipidemia should avoid it. Rapamycin can elevate triglycerides and LDL. Anyone taking medications that interact with CYP3A4 needs careful monitoring. A physician familiar with longevity medicine is required.

Is the rapamycin-acarbose combination being tested in humans?

Not yet as of 2026. The combination data comes from ITP mouse studies showing 28 to 34% median lifespan extension. Human pilot trials are in planning. Acarbose’s strong safety record from decades of diabetes use lowers the regulatory barriers considerably.

What is the difference between rapamycin and sirolimus?

They are the same drug. Sirolimus is the pharmaceutical-grade generic name. Rapamycin is the original discovery name. Compounded versions may have different bioavailability than pharmaceutical-grade sirolimus, as PEARL documented at roughly a 3-to-1 ratio.

Conclusion

The PEARL trial gave the longevity field something it has needed for years: real, placebo-controlled human data on low-dose intermittent rapamycin. The primary endpoint missed. The secondary data, particularly the 5% lean tissue gain in women and the favorable 48-week safety profile, is a meaningful signal that keeps mTOR inhibition firmly on the research agenda.

The drug worked in mice starting in middle age. The first human trial suggests it is safe at low weekly doses and produces real changes in at least one tissue in at least one population. That is not nothing. It is not proof of longevity benefit either. It is the foundation for the next generation of trials.

If you are not doing resistance training, eating adequate protein, and incorporating some form of fasting, those interventions target the same pathways with decades of human safety data behind them. They are the foundation. Rapamycin, for those who pursue it under physician guidance, may add to that foundation in ways that will become clearer as longer and larger trials arrive.

Related reading on EverStayYoung:

• Berberine vs. Metformin for Longevity: What the Evidence Shows
• Senolytics in Human Trials: What We Know So Far
• Alpha-Ketoglutarate and Aging: What the Evidence Shows

References

1. Mannick JB, et al. “Safety and efficacy of rapamycin on healthspan metrics after one year: PEARL Trial Results.” 2025. PMID 40188830 / PMC12074816
2. Harrison DE, et al. “Rapamycin fed late in life extends lifespan in genetically heterogeneous mice.” Nature. 2009. PMID 19587680
3. Strong R, et al. “Rapamycin-mediated mouse lifespan extension: late-life dosing regimens with sex-specific effects.” Aging Cell. 2022. PMC9741502
4. Guo S, et al. “Dual mTOR and MEK inhibition extends mouse lifespan.” Frontiers in Aging. 2025.
5. npj Aging. “Physical activity and epigenetic clocks in 948 adults.” 2025. PMID 40221397
6. Journal of Cachexia, Sarcopenia and Muscle. 2026. PMID 40511567